| Rituximab (RTX), azathioprine (AZA), and mycophenolate mofetil (MMF) are effective, with significant improvements in the Expanded Disability Status Scale (EDSS) and annualized relapse rate (ARR), regardless of the seropositive or seronegative aquaporin-4 antibody status. |
| RTX is recommended as the first-line therapy in patients with neuromyelitis optica spectrum disorders rather than AZA and MMF, in view of its effectiveness and safety. |
| Low dosage of RTX could be recommended for patients with neuromyelitis optica owing to its long-term effectiveness and safety. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.